If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cyramza Summary of Product Characteristics (SmPC)
Cyramza® (ramucirumab): Preparation and concentration range
Prepare as directed below using aseptic technique and sterile sodium chloride (0.9%) solution as a diluent to achieve a final volume of 250 mL in the concentration range 0.4 to 4.0 mg/mL.
the infusion solution using aseptic technique to ensure the sterility
of the prepared solution.1
vial of ramucirumab is intended for single use only.1
the contents of the vials for particulate matter and discoloration
prior to dilution. The color should be clear to slightly opalescent
and colorless to slightly yellow without visible particles. If
particulate matter or discolorations are identified, discard the
the dose and the required volume of ramucirumab needed to prepare
the infusion solution. Vials contain either 100 mg or 500 mg as a 10
mg/ml solution of ramucirumab. Only use sodium chloride 9 mg/ml
(0.9%) solution for injection as a diluent.
ramucirumab as required to achieve a final volume of 250 mL. Only
use sterile sodium chloride (0.9%) solution for injection as a
case of prefilled intravenous (IV) infusion container usage:
based on the calculated volume of ramucirumab, remove the
corresponding volume of sterile sodium chloride (0.9%) solution for
injection from the prefilled 250-mL IV container. Aseptically
transfer the calculated volume of ramucirumab to the IV container.
The final total volume in the container should be 250 mL.
case of empty IV infusion container usage: aseptically
transfer the calculated volume of ramucirumab into an empty IV
container. Add a sufficient quantity of sterile sodium chloride
(0.9%) solution for injection to the container to make the total
volume 250 mL.
container should be gently inverted to ensure adequate mixing.
not freeze or shake the infusion solution.
not dilute with other solutions or co-infuse with other
electrolytes or medication.
drug products should be inspected visually for particulate matter
prior to administration. If particulate matter is identified,
discard the infusion solution.
any unused portion of ramucirumab left in a vial, as the product
contains no preservatives.1,2
information on final volume and concentration range
does not have specific data to support diluting ramucirumab to
concentrations below 0.4 mg/mL (ie, 10 mL of the 100 mg/10mL vial
diluted with sodium chloride [0.9%] solution for injection to a final
volume of 250 mL).
concentration of ramucirumab in the prepared dose must be within 0.4
to 4.0 mg/mL. Larger containers (ie, 500 ml) of sodium chloride
(0.9%) solution for injection may be used if adjusted to the target
dose volume of 250 mL and the concentration of ramucirumab in the
prepared dose is within 0.4 to 4.0 mg/mL.1
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Cyramza [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Date of Last Review:August 09, 2019
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com